Limits Polymorphonuclear Leukocytes Recruitment to Inflammatory Loci Receptor-Dependent Actions
暂无分享,去创建一个
M. Perretti | R. Flower | C. Serhan | L. Norling | J. Dalli
[1] J. Werba,et al. Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] Ji Min Kim,et al. Chemical Mediators of Inflammation and Resolution in Post-Operative Abdominal Aortic Aneurysm Patients , 2012, Inflammation.
[3] C. Serhan,et al. Metabolomics‐Lipidomics of Eicosanoids and Docosanoids Generated by Phagocytes , 2011, Current protocols in immunology.
[4] C. Serhan,et al. Impaired Phagocytosis in Localized Aggressive Periodontitis: Rescue by Resolvin E1 , 2011, PloS one.
[5] K. Swedberg. n-3 Fatty acids in cardiovascular disease. , 2011, The New England journal of medicine.
[6] Sriram Krishnamoorthy,et al. MicroRNAs in resolution of acute inflammation: identification of novel resolvin Dl‐miRNA circuits , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[7] C. Serhan,et al. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. , 2010, Circulation research.
[8] M. Perretti,et al. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin‐derived peptide‐stimulated phagocytosis , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[9] C. Serhan,et al. Resolvin E1 Regulates Adenosine Diphosphate Activation of Human Platelets , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[10] M. Perretti,et al. Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists. , 2010, Pharmacology & therapeutics.
[11] J. Cowland,et al. Neutrophil granules in health and disease , 2010, Journal of internal medicine.
[12] D. Gilroy,et al. Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways , 2010, Proceedings of the National Academy of Sciences.
[13] R. Hannon,et al. Anti-Inflammatory Role of the Murine Formyl-Peptide Receptor 2: Ligand-Specific Effects on Leukocyte Responses and Experimental Inflammation , 2010, The Journal of Immunology.
[14] C. Serhan,et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors , 2010, Proceedings of the National Academy of Sciences.
[15] J. Takeda,et al. The Anti-Inflammatory and Proresolving Mediator Resolvin E1 Protects Mice from Bacterial Pneumonia and Acute Lung Injury , 2009, The Journal of Immunology.
[16] M. Perretti,et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis , 2009, Nature.
[17] Marc Parmentier,et al. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family , 2009, Pharmacological Reviews.
[18] Sheng-hua Wu,et al. Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis. , 2009, The American journal of pathology.
[19] M. Toner,et al. Rapid Appearance of Resolvin Precursors in Inflammatory Exudates: Novel Mechanisms in Resolution1 , 2008, The Journal of Immunology.
[20] C. Serhan,et al. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] K. Urabe,et al. Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis. , 2007, The Journal of rheumatology.
[22] M. Cybulsky,et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated , 2007, Nature Reviews Immunology.
[23] Charles N. Serhan,et al. Resolvin E1 and protectin D1 activate inflammation-resolution programmes , 2007, Nature.
[24] J. Uddin,et al. Resolvin D1 and Its Aspirin-triggered 17R Epimer , 2007, Journal of Biological Chemistry.
[25] A. Hashimoto,et al. Glucocorticoids co-interact with lipoxin A4 via lipoxin A4 receptor (ALX) up-regulation. , 2007, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[26] Takao Shimizu,et al. The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo , 2006, Pharmacological Reviews.
[27] John Savill,et al. Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.
[28] C. Serhan,et al. Molecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins1 , 2005, The Journal of Immunology.
[29] Adriano G. Rossi,et al. Inflammatory Resolution: new opportunities for drug discovery , 2004, Nature Reviews Drug Discovery.
[30] C. Serhan,et al. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[31] A. Simopoulos. Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases , 2002, Journal of the American College of Nutrition.
[32] Charles N. Serhan,et al. Lipid mediator class switching during acute inflammation: signals in resolution , 2001, Nature Immunology.
[33] C. Clish,et al. Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing , 2000, The Journal of experimental medicine.
[34] H. Heng,et al. Cloning genes encoding receptors related to chemoattractant receptors. , 1998, Genomics.
[35] C. Clish,et al. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. , 1998, The Journal of clinical investigation.
[36] Larry V. McIntire,et al. Leucocyte adhesion under flow conditions: principles important in tissue engineering. , 1996, Biomaterials.